26 Amendments of Jessica POLFJÄRD related to 2023/2075(INI)
Amendment 11 #
Motion for a resolution
Citation 6 a (new)
Citation 6 a (new)
Amendment 98 #
Motion for a resolution
Recital D a (new)
Recital D a (new)
Da. whereas, according to Article 168 TFEU, the European Union can play a cooperative and complimentary role with regard to healthcare, while health at its core constitutes a national competence;
Amendment 113 #
Motion for a resolution
Recital E
Recital E
E. whereas most NCDs are impacted by four preventable risk factors: combustion tobacco use, unhealthy diet, lack of physical activity and harmful use of alcohol; whereas behavioural risk factors lead to biological risk factors, the most common being overweight and obesity, high blood pressure, high blood glucose and high blood cholesterol6 ; _________________ 6 World Health Organization, ‘Monitoring noncommunicable disease commitments in Europe 2021’, p. 13, 8 December 2021.
Amendment 183 #
Motion for a resolution
Recital H
Recital H
H. whereas innovation with regard to development of technologies, medicines and healthcare practises, and harm reduction policies is crucial to ensure the elimination or reduction of harm caused by preventable risk factors and new and better treatments for NCDs;
Amendment 255 #
3. Acknowledges that combustion tobacco use, physical inactivity, the harmful use of alcohol, unhealthy diets and environmental factors such as air, food, water and soil pollution and chemical exposure increase the risk of NCDs10 ; _________________ 10 https://www.paho.org/en/topics/noncommu nicable-diseases - :~:text=These%204%20groups%20of%20d iseases,of%20the%20response%20to%20N CDs The Pan American Health Organization, ‘Noncommunicable Diseases’.
Amendment 265 #
Motion for a resolution
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Acknowledges the complex and multifactorial causes of NCDs and that NCDs cannot always be prevented, and that even among preventable NCDs, there are many cases that cannot be explained by preventable risk factors and that many NCDs display a high degree of hereditary risk;
Amendment 295 #
Motion for a resolution
Paragraph 5 – point a
Paragraph 5 – point a
a. implement measures to help tobacco users quit, reduce the rate of new tobacco users, and prevent tobacco use among minors;
Amendment 310 #
Motion for a resolution
Paragraph 5 – point b
Paragraph 5 – point b
b. follow up on the scientific evaluations of the health risks related to electronic cigarettes, heated tobacco products and novel tobacco products including the assessment of the relative risks of using these products compared to consuming other tobacco products, and the role these products can play in reducing smoking in the Union;
Amendment 318 #
Motion for a resolution
Paragraph 5 – point b a (new)
Paragraph 5 – point b a (new)
Amendment 402 #
Motion for a resolution
Paragraph 8 – point a
Paragraph 8 – point a
a. encourage and help consumers to make informed and healthy choices about food products; promote behavioural changes via communication and mass media campaigns for healthy diets; encourage public food procurement and service policies for healthy and sustainable diets; mainstream physical activities such as walking, cycling, and the practice of sports in urban planning, and put an increased emphasis on physical activity in schools;
Amendment 475 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Considers the European Green Deal to be instrumental in preventing NCDs in the EU by reducing air, food, water and soil pollution and chemical exposure; highlights that prevention of chronic respiratory diseases besides tobaccocombustion cigarette cessation also includes the prevention of exposure to dust and other indoor pollutants;
Amendment 511 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Regrets the slowCalls on the Commission to continuously implementation of the Chemicals Strategy for Sustainability, and, in particular, expects the REACH Regulation18 to be revised, including in line with the Better Regulation principles, in order to be able to identify all substances of concern manufactured or imported in the EU; _________________ 18 Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), OJ L 396, 30.12.2006, p. 1.
Amendment 556 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Highlights the importance of identifying people with a high risk of developing NCDs and diagnosing people as early as possible to improve disease management, prevent complications and save downstream costs for healthcare systems; calls for the systematic exchange at the European level of best practice regarding screening for and early detection of NCDs, such as prostate and cervical cancer; welcomes the updated Council recommendation on cancer screening and calls on Member States to implement it diligently;
Amendment 583 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Encourages Member States to reduce undiagnosed NCDs by introducing targeted health checks for high-risk individuals and individuals belonging to vulnerable and marginalised groups, addressing the main shared metabolic risk factors, ensuring quality care and support NCD patients’ self- management; highlights the importance of privacy and medical confidentiality in this regard;
Amendment 603 #
Motion for a resolution
Paragraph 17 a (new)
Paragraph 17 a (new)
17a. Highlights the link between oral health, including pariodental disease and caries, and some NCDs, such as diabetes and cardiovascular diseases, and the potential positive effects on NCDs of improved oral health;
Amendment 634 #
Motion for a resolution
Paragraph 18 a (new)
Paragraph 18 a (new)
18a. Stresses the importance of cost- effective healthcare, so that limited resources are put to the best use and to the use of patients in most need;
Amendment 655 #
Motion for a resolution
Paragraph 19
Paragraph 19
19. Believes that every patient is different and no NCD is the same; calls for NCDs to be prevented and treated as effectively as possible, with a personalised approach tailored to the patient and the disease, while taking Member States' need for an efficient organisation of healthcare into account;
Amendment 662 #
Motion for a resolution
Paragraph 19 a (new)
Paragraph 19 a (new)
19a. Notes that NCDs can have a significant negative effect on mental health, and stresses the need for integrated healthcare for concerned patients; stresses that negative stereotypes related to certain NCDs, notably obesity, can be counterproductive in healthcare and prevention while recalling individual responsibility for certain risk factors;
Amendment 704 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Recalls that patient empowerment and, health literacy, and treatment adherence are crucial for an EU NCD strategy and that treatment and care should be patient- centred; encourages the promotion of well- informed patients who are actively involved in their own treatment and calls for the therapeutic training of caregivers and patients and their empowerment in the care programmes; underlines the importance of therapeutic adherence, in order to lower hospitalisation and mortality rates as well as optimise the impact of medical investments; encourages Member States to provide healthcare professionals with training regarding patient therapeutic education;
Amendment 710 #
Motion for a resolution
Paragraph 20 a (new)
Paragraph 20 a (new)
20a. Highlights that patient stigma should be counteracted and mitigated at the national level;
Amendment 715 #
Motion for a resolution
Paragraph 21
Paragraph 21
21. Notes the need to focus on the quality of life of NCD patients whose illnesses cannot be cured but may be stabilised for a number of years; emphasises the importance of specific EU recommendations to improve the quality of life of patients including by integrating comprehensive supportive care into care, starting with the diagnosis and continuing over the course of the disease and by granting access to specialised support centres;
Amendment 736 #
Motion for a resolution
Paragraph 22
Paragraph 22
22. Welcomes the pharmaceutical package and calls for the strengthening of the European medicines market to ensure access to medicines and alleviate medicine shortages, reduce barriers to cross-border business, while strengthening incentives for investment in innovation; underlines that upheld regulatory data protection and intellectual property rights are crucial to ensure competitiveness in the EU by incentivising innovators to develop new products and further ongoing research efforts;
Amendment 756 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Highlights the potential of the private sector with respect to disease control and healthcare; Welcomes public- private partnerships as a way of strengthening innovation in healthcare; highlights the European Health Innovation Collaborative, which promotes entrepreneurship and innovation in the healthcare sector and brings together academia, research, and industry to foster collaboration and investment in health technologies; encourages the Commission and the Member States to foster and accelerate public-private partnerships;
Amendment 762 #
Motion for a resolution
Paragraph 23 a (new)
Paragraph 23 a (new)
23a. Highlights that publicly funded research should prioritise promising products and methods characterised by limited commercial interest, non- patentability, and low benefits in scaleability;
Amendment 765 #
Motion for a resolution
Paragraph 24
Paragraph 24
24. Calls on the Commission to strengthen support and investment in the development of new innovative medical devices; believes that new technologies can lead to new and better treatments for NCDs; notes the slow uptake of medical devices under the current Medical Devices Regulation and In Vitro Diagnostic Devices Regulation, and welcomes the postponement of application of certain provisions; calls on the Commission to evaluate the specific needs for the pediatric and orphan medical devices sectors, and propose any legislative amendments necessary to ensure the continuous supply for these patient groups;
Amendment 806 #
Motion for a resolution
Paragraph 26
Paragraph 26
26. Calls on the Commission to establish fivprepare EU NCD partnerships: ‘beating NCDs – children’, ‘beating NCDs – young, based on diseases or people, ‘beating NCDs – adults’, ‘beating NCDs – elderly people’ and ‘beating NCDs – vulnerable groups’ulation groups, as appropriate; believes that such partnerships shcould bring together Member States and national authorities to draft roadmaps and innovative proposals to ensure effective and targeted actions against NCDs;